Ann: Half Yearly Report and Accounts, page-21

Agreed, The announcement of completion, as with permission from the DSMB to proceed is a price sensitive announcement so has to be made by LCT upon the satisfactory completion of the Treatment.

Going to be a very interesting week, Ken to speak on Tuesday so I bet Ken would love to be able to discuss how the procedures went etc at the BioTech summer reception.

I'm hoping to see some extensive media surrounding the completion of the Treatment phase of the Phase II trials. LCT is New Zealands Premier Biotech Company and deserves some decent press and media exposure.